Literature DB >> 17382543

SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction.

Fraser Hunt1, Caroline Austin, Rupert Austin, Roger Bonnert, Peter Cage, Jadeen Christie, Mark Christie, Clare Dixon, Steven Hill, Robert Jewell, Ian Martin, David Robinson, Paul Willis.   

Abstract

As part of a Lead Optimisation programme to identify small molecule antagonists of the human CXCR2 receptor, a series of substituted thiazolo[4,5-d]pyrimidines was prepared via the application of a novel tandem displacement reaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17382543     DOI: 10.1016/j.bmcl.2007.02.080

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  A rapid access to novel and diverse 3-oxothiazolo[3,2-c]pyrimidine-8-carboxylates using multicomponent Mannich cyclisation reactions.

Authors:  Muhammet Yıldırım; Derya Çelikel
Journal:  Mol Divers       Date:  2014-08-24       Impact factor: 2.943

Review 2.  Neutrophils: key mediators of tumour angiogenesis.

Authors:  Simon Tazzyman; Claire E Lewis; Craig Murdoch
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

3.  A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling.

Authors:  Helen Ha; Tim Bensman; Henry Ho; Paul M Beringer; Nouri Neamati
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

4.  Discovery of 1,5-Dihydro-4H-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2.

Authors:  Jinxin Che; Zhilong Wang; Zheyuan Shen; Weihao Zhuang; Huazhou Ying; Yongzhou Hu; Youhong Hu; Xin Xie; Xiaowu Dong
Journal:  ACS Med Chem Lett       Date:  2021-04-08       Impact factor: 4.345

Review 5.  Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.

Authors:  Helen Ha; Bikash Debnath; Nouri Neamati
Journal:  Theranostics       Date:  2017-04-07       Impact factor: 11.556

6.  Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer.

Authors:  Laura M Campbell; Pamela J Maxwell; David J J Waugh
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.